The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination

https://doi.org/10.1016/0049-0172(89)90050-4Get rights and content

Abstract

Atabrine has been available for nearly 60 years. It has a variety of actions and has been administered to millions of individuals. Its antirheumatic properties have been well documented but have not been exploited optimally for a variety of reasons. The drug is generally quite safe and could be used in low doses in lupus and rheumatoid arthritis patients as a steroid-sparing agent or synergistically with hydroxychloroquine. Its bothersome side effects should not deter the clinician from using it, because they are easy to deal with or prevent (Table 5). Future studies should attempt to better characterize the immunosuppressive actions of this powerful drug, particularly in the treatment of lupus erythematosus and rheumatoid arthritis. Studies of the role of combination or single-agent antimalarial therapy in combination with other “remittive” drugs could be of great potential benefit.

References (220)

  • H.R. Holman et al.

    Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein

    Science

    (1957)
  • J Nagai et al.

    Inhibition of oxidative hemolysis and lipid peroxidation by mepacrine

    J Biochem (Tokyo)

    (1981)
  • N.G. Read et al.

    The uptake by horse polymorpho-nuclear leucocytes in vitro

    J Pharm Pharmacol

    (1982)
  • D Tighe et al.

    A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits

    Intens Care Med

    (1987)
  • P.C. Panus et al.

    Inhibition of neutrophil response by mepacrine

    Biochem Pharmacol

    (1987)
  • A Baba et al.

    Inhibition of quinacrine of depolarization-induced acetylcholine release and calcium influx in rat brain cortical synaptosomes

    J Neurochem

    (1983)
  • E Nagy et al.

    Experiments on the antihistaminic action of atabrine

    Derm Wscr

    (1956)
  • H Juan

    Inhibition of the algesic effect of bradykinin and acetylcholine by mapacrine

    Naunyn Schmiedebergs Arch Pharmacol

    (1977)
  • M.K. Bach

    Reduction in the frequency of mutation or to resistance to cytarabine in L1210 murine leukemia cells by treatment with quinacrine hydrochloride

    Cancer Res

    (1969)
  • M Alund et al.

    Release of (14C) quinacrine from peripheral and central nerves

    J Auton Nerv Syst

    (1980)
  • C Spies et al.

    Inhibitory effects of mecaprine and eicosatetraynoic acid on cyclic GMP elevations caused by calcium and hormonal factors in rat ductus deferens

    Naunun Schmiedebergs Arch Pharmacol

    (1980)
  • T.Y. Lot

    The in vitro pharmachology of chloroquine and quinacrine

    Med Biol

    (1986)
  • C.F. Saladino et al.

    Quinacrine-enhanced killing response of cultured Chinese hamster cells by x-rays

    Res Commun Chem Pathol Pharmacol

    (1978)
  • H Schadewaldt

    Introduction of atebrine into materia medica

    Dtsch Med Wochenschrift

    (1975)
  • W Schulemann

    Synthetic antimalarial drugs

    Br Med J

    (1932)
  • Office of the Surgeon General

    Circular letter no. 153; The drug treatment of malaria, suppressive and clinical

    JAMA

    (1943)
  • L.S. Goodman et al.

    The Pharmacological Basis of Therapeutics

  • A.J. Prokoptchouk

    Traitment du loup erythemateux par l'ariquine

    Zentralbl Haut Geschlechskr

    (1940)
    A.J. Prokoptchouk

    Traitment du loup erythemateux par l'ariquine

    Vestnik Venerol Dermatol

    (1940)
    A.J. Prokoptchouk

    Traitment du loup erythemateux par l'ariquine

    Arch Dermatol Syph

    (1955)
  • N.S. Sorinson

    Acrichin in therapy of lupus erythematosus

    Vrach Delu

    (1941)
  • F Page

    Treatment of lupus erythematosus with mecaprine

    Lancet

    (1951)
  • Package insert: Atabrine hydrochloride

    (1984)
  • J.A. Shannon et al.

    The pharmacological basis for rational use of atabrine in treatment of malaria

    J Pharmacol Exp Ther

    (1944)
  • F Ottolenghi-Lodigianti

    Local intradermal application of acridine preparations for treatment of chronic lupus erythematosus

    Hautarzt

    (1955)
  • W Thies

    Recent experiences in treatment of chronic discoid lupus erythematosus with atabrine and chloroquine, particularly with local and combined therapy

    Hautarzt

    (1955)
  • J Zipper et al.

    The clinical efficacy of the repeated transcervical instillation of quinacrine for female sterilization

    Int J Gynaecol Obstet

    (1976)
  • J Zipper et al.

    Efficacy of two insertions of 100-minute releasing quinacrine hydrochloride pellets for non-surgical female sterilization

    Adv Contracept

    (1987)
    J Zipper et al.

    Efficacy of two insertions of 100-minute releasing quinacrine hydrochloride pellets for non-surgical female sterilization

    Adv Contracept

    (1987)
  • T.C. Bayly et al.

    Tetracycline and quinacrine in the control of malignant pleural effusions. A randomized trial

    Cancer

    (1978)
  • D.F. Horrobin et al.

    Quinacrine is a prostaglandin antagonist

    Biochem Biophys Res Comm

    (1977)
  • C.A. Dise et al.

    Direct interaction of mecaprine with erythrocyte and platelet membrane phospholipid

    J Biol Chem

    (1982)
  • P.M. Evans et al.

    Effects of inhibitors of arachidonic acid metabolism on intercellular adhesion of SV40-3T3 cells

    Cell Biol Int Rep

    (1986)
  • K.S. Authi et al.

    Stimulation of polymorphonuclear leucocyte phospholipase A2 activity by chloroquine and mepacrine

    J Pharm Pharmacol

    (1982)
  • J.T. Flynn

    Inhibition of complement-mediated hepatic thromboxane production by mepacrine, a phospholipase inhibitor

    Prostaglandins

    (1987)
  • P.D. Winocour et al.

    The effect of phospholipase inhibitor on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface

    Thromb Haemost

    (1981)
  • I Matsuoka et al.

    Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets

    J Cyclic Nucleotide Protein Phosphor Res

    (1983)
  • J.M. McCrea et al.

    Mecaprine (quinacrine) inhibition of thrombin-induced platelet responses can be overcome by lysophosphatidic acid

    Biochim Biophys Acta

    (1985)
  • T Yamakado et al.

    Mepacrine-induced inhibition of human platelet cyclic-GMP phosphodiesterase

    Biochim Biophys Acta

    (1984)
  • D.J. Wallace

    Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?

    Arthritis Rheum

    (1987)
  • S Doglia et al.

    Specific interactions between quinacrine and self-complementary deoxynucleotides

    Anticancer Res

    (1986)
  • A.T. Sumner

    Mechanisms of quinacrine binding and fluorescence in nuclei and chromosomes

    Histochemistry

    (1986)
  • N Xamena et al.

    Testing of chloroquine and quinacrine for mutagenicity in Drosophila melanogaster

    Mutat Res

    (1985)
  • Cited by (132)

    • Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept

      2021, European Journal of Pharmacology
      Citation Excerpt :

      Chloroquine was synthesized in 1934 by Johann (Hans) Andersag at Bayer A.G. by replacing the acridine with a quinoline ring in quinacrine (Atabrine) and was used under the name Resochin; in 1945 it was rediscovered by E.K. Marshall and received its current name (Krafts et al., 2012), remaining for decades a first-line antimalarial therapy. The mechanisms of action of quinoline antimalarials in autoimmune diseases are complex (Chew et al., 2020; Haładyj et al., 2018; Wallace, 1989). The antiviral activity of chloroquine and hydroxychloroquine is deemed to result from accumulation of the protonated charged form in the acidic environment of endosomes, lysosomes and Golgi vesicles, leading to increased internal endosomal pH, thus preventing their use by viral particles as entry gateways (Ducharme and Farinotti, 1996).

    • First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer

      2021, Clinical Colorectal Cancer
      Citation Excerpt :

      Acridine is a compound first isolated from coal tar, and its analogs, such as CP-31398, have been shown to restore p53 functioning.10 Quinacrine is an acridine derivative that was developed over 90 years ago as an antimalarial drug and has since been used to treat many rheumatic and infectious diseases.11 We found that quinacrine induces p53 pathway-dependent transcription in p53-deficient cells, leading to apoptosis in tumor xenografts.12

    • Connective Tissue Disease: Current Concepts

      2019, Dermatologic Clinics
      Citation Excerpt :

      Quinacrine has the advantage of not being associated with retinal toxicity, unlike HCQ and CQ. Studies have also suggested quinacrine may be a stronger antiinflammatory agent than HCQ or CQ, and recently it was shown to more effectively suppress both tumor necrosis factor-α and IFN-α in peripheral blood mononuclear cells from patients with DM and CLE.32,33 Importantly, multiple studies have been performed recently that can potentially be translated into safer and more effective use of antimalarials for CLE in everyday clinical practice.

    View all citing articles on Scopus
    1

    From the Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles.

    View full text